Delving into the Latest Updates on Microbiotix, Inc. with Synapse

Overview

Basic Info

Introduction

Microbiotix, Inc. is a privately-owned corporation headquartered in Worcester, Massachusetts, specializing in pharmaceutical formulations. The company was established by Wendy E. Rieder. According to the company's website, their focus is on identifying and developing innovative drugs that combat serious infectious diseases and drug-resistant pathogens. Their primary project, MBX-400, is a potent nucleoside dual DNA polymerase/kinase inhibitor designed for managing cytomegalovirus (CMV) disease in transplant patients, and it is ready for Phase 2 trials.

Tags

Infectious Diseases

Respiratory Diseases

Other Diseases

Small molecule drug

Microbiota

Antitoxin

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	9

Top 5 Drug Type	Count

Small molecule drug	7
Microbiota	1
Antitoxin	1

Top 5 Target	Count

hemagglutinin(Influenza virus hemagglutinin glycoproteins)	2
Bacterial DNA gyrase x DNA polymerase x TOP	1
Proton pump	1

Human cytomegalovirus (HCMV) is a β-herpesvirus that contributes to the disease burden of immunocompromised and immunomodulated individuals, including transplant recipients and newborns. The FDA-approved HCMV drugs can exhibit drug resistance and severe side effects including bone marrow toxicity, gastrointestinal disruption, and nephrotoxicity. In a previous study, we identified the N-arylpyrimidinamine (NAPA) compound series as a new class of HCMV inhibitors that target early stages of infection. Here we describe the inhibitory activity of two potent NAPA analogs, MBXC-4336 and MBX-4992, that broadly block infection and spread. MBXC-4336 and MBX-4992 effectively inhibited infection by diverse HCMV strains and significantly prevented virus spread in fibroblast and epithelial cells as evaluated by quantifying infected cells and viral genome levels. Further, the NAPA compounds limited replication of clinical HCMV isolates, including a ganciclovir-resistant strain. Importantly, combination studies of NAPA compounds with ganciclovir demonstrated additive or synergistic inhibition of HCMV spread. Collectively, NAPA compounds have therapeutic potential for development as a novel class of anti-HCMV drugs.

06 Nov 2024·Antimicrobial Agents and Chemotherapy

Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis

Article

Author: Meibohm, Bernd ; Zimmerman, Matthew D. ; Jones, Isabelle L. ; Hastings, Courtney ; Dartois, Veronique ; Bauman, Allison A. ; Brooks, Elizabeth J. ; Ramey, Michelle E. ; Massoudi, Lisa M. ; Kaya, Firat ; Robertson, Gregory T. ; Liu, Jiuyu ; Gonzalez-Juarrero, Mercedes ; Waidyarachchi, Samanthi L. ; Lenaerts, Anne J. ; Bowlin, Terry L. ; Xie, Min ; Maclaughlin, Madelyn R. ; Sarathy, Jansy P. ; Lee, Richard E. ; Butler, Michelle M. ; Benedict, Noalani D. ; Scherman, Michael S. ; Miller-Dawson, Jake A. ; Lyons, Michael A.

ABSTRACT The spectinamides are novel, narrow-spectrum semisynthetic analogs of spectinomycin, modified to avoid intrinsic efflux by Mycobacterium tuberculosis . Spectinamides, including lead MBX-4888A (Lee-1810), exhibit promising therapeutic profiles in mice, as single drugs and as partner agents with other anti-tuberculosis antibiotics including rifampin and/or pyrazinamide. Here, we show that MBX-4888A, given by injection with the front-line standard of care regimen, is treatment shortening in multiple murine tuberculosis infection models. The positive treatment responses to MBX-4888A combination therapy in multiple mouse models, including mice exhibiting advanced pulmonary disease, can be attributed to favorable distribution in tissues and lesions, retention in caseum, along with favorable effects with rifampin and pyrazinamide under conditions achieved in necrotic lesions. This study also provides an additional data point regarding the safety and tolerability of spectinamide MBX-4888A in long-term murine efficacy studies.

08 Dec 2023·ACS Infectious Diseases

Cell-Based Assay to Determine Type 3 Secretion System Translocon Assembly in Pseudomonas aeruginosa Using Split Luciferase

Article

Author: Opperman, Timothy J. ; Guo, Hanling ; Heuck, Alejandro P. ; Geddes, Emily J.

Multi-drug-resistant Pseudomonas aeruginosa poses a serious threat to hospitalized patients. This organism expresses an arsenal of virulence factors that enables it to readily establish infections and disseminate in the host. The Type 3 secretion system (T3SS) and its associated effectors play a crucial role in the pathogenesis of P. aeruginosa, making them attractive targets for the development of novel therapeutic agents. The T3SS translocon, composed of PopD and PopB, is an essential component of the T3SS secretion apparatus. In the properly assembled translocon, the N-terminus of PopD protrudes into the cytoplasm of the target mammalian cell, which can be exploited as a molecular indicator of functional translocon assembly. In this article, we describe a novel whole-cell-based assay that employs the split NanoLuc luciferase detection system to provide a readout for translocon assembly. The assay demonstrates a favorable signal/noise ratio (13.6) and robustness (Z' = 0.67), making it highly suitable for high-throughput screening of small-molecule inhibitors targeting T3SS translocon assembly.

100 Deals associated with Microbiotix, Inc.

Login to view more data

100 Translational Medicine associated with Microbiotix, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

9

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Spectinamides	Tuberculosis More	Preclinical
GON-X	Neisseriaceae Infections More	Preclinical
Aminospectinomycins	Tularemia More	Preclinical
MBX2546 ( hemagglutinin )	Influenza A virus infection More	Preclinical
VAP-X	Infectious Diseases More	Preclinical